{"id":11488,"date":"2020-11-20T18:02:39","date_gmt":"2020-11-20T23:02:39","guid":{"rendered":"https:\/\/www.progeriaresearch.org\/?p=11488"},"modified":"2022-11-14T17:17:52","modified_gmt":"2022-11-14T22:17:52","slug":"fda-approval","status":"publish","type":"post","link":"https:\/\/www.progeriaresearch.org\/ps\/2020\/11\/20\/fda-approval\/","title":{"rendered":"\u0648\u0631\u0681 \u0631\u0627\u063a\u0644\u0647: \u062f \u0644\u0648\u0645\u0693\u064a \u0681\u0644 \u0644\u067e\u0627\u0631\u0647 \u062f \u067e\u0631\u0648\u062c\u06cc\u0631\u06cc\u0627 \u062f\u0631\u0645\u0644\u0646\u06d0 \u0644\u067e\u0627\u0631\u0647 \u062f FDA \u062a\u0635\u0648\u06cc\u0628!"},"content":{"rendered":"<p>[et_pb_section fb_built=&#8221;1&#8243; _builder_version=&#8221;4.16&#8243; global_colors_info=&#8221;{}&#8221;][et_pb_row _builder_version=&#8221;4.16&#8243; background_size=&#8221;initial&#8221; background_position=&#8221;top_left&#8221; background_repeat=&#8221;repeat&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;4_4&#8243; _builder_version=&#8221;4.16&#8243; custom_padding=&#8221;|||&#8221; global_colors_info=&#8221;{}&#8221; custom_padding__hover=&#8221;|||&#8221;][et_pb_text admin_label=&#8221;FDA&#8221; _builder_version=&#8221;4.18.1&#8243; background_size=&#8221;initial&#8221; background_position=&#8221;top_left&#8221; background_repeat=&#8221;repeat&#8221; hover_enabled=&#8221;0&#8243; global_colors_info=&#8221;{}&#8221; sticky_enabled=&#8221;0&#8243;]<\/p>\n<p style=\"font-weight: 400;\"><strong><img loading=\"lazy\" decoding=\"async\" class=\"wp-image-11496 size-medium alignleft\" src=\"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2020\/11\/FDA-page-169x300.jpg\" alt=\"\" width=\"169\" height=\"300\" srcset=\"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2020\/11\/FDA-page-169x300.jpg 169w, https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2020\/11\/FDA-page.jpg 300w\" sizes=\"(max-width: 169px) 100vw, 169px\" \/><\/strong>Breaking, exciting news! On November 20, 2020, PRF achieved an important piece of our mission: <strong>lonafarnib, the first-ever treatment for Progeria, has been granted FDA approval<\/strong>.<\/p>\n<p>Progeria now joins less than\u00a0<strong>5% of the rare diseases with an FDA-approved treatment.*\u00a0<\/strong>Children and young adults with Progeria in the U.S. may now access lonafarnib by prescription, instead of through a clinical trial.<\/p>\n<p>This momentous milestone has arrived thanks to 13 steadfast years of research involving <a href=\"https:\/\/www.progeriaresearch.org\/clinical-trials\/\">four clinical trials<\/a>, all co-coordinated by PRF, made possible by the courageous children and their families, and funded by you, PRF\u2019s wonderful community of donors.<\/p>\n<p>We\u2019re also grateful to the world-class Progeria research teams at Boston Children\u2019s Hospital, Hasbro Children\u2019s Hospital, Brigham and Women\u2019s Hospital, Brown University, Boston University, and the National Institutes of Health. Pharmaceutical partners that supplied lonafarnib free of charge to PRF-supported clinical trials were crucial as well, including Shering-Plough, Merck ** (known as MSD outside the U.S. and Canada) and Eiger BioPharmaceuticals, for their part in advancing progress in Progeria research to these extraordinary new heights.<\/p>\n<p>Our partners at Eiger are committed to providing continuous access to lonafarnib for patients with Progeria and processing-deficient Progeroid Laminopathies worldwide, and they\u2019ve established services to support access to lonafarnib through <em>Eiger OneCare, <\/em>as well as through Eiger\u2019s Managed Access Program for patients outside the U.S. The European Medicines Agency (EMA) review of lonafarnib is still ongoing, with a decision on EMA approval expected in the second half of 2021.<\/p>\n<p>THANK YOU ALL for supporting the research that has brought us to this pivotal point. Your continued support also allows us to keep pressing forward toward a cure for these extraordinary children.<\/p>\n<p><strong>What a truly remarkable way to begin the holiday season and end this incredibly<\/strong><strong> challenging<\/strong> <strong>year.<\/strong><\/p>\n<p><a href=\"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2020\/11\/PRF-Press-Release-Zokinvy-FDA-Approval-FINAL.pdf\" rel=\"attachment wp-att-11508\">Click here for our press release<\/a> which provides more details on this historic news.<\/p>\n<p>*300 rare diseases that have an FDA-approved treatment (<a href=\"https:\/\/www.rarediseases.info.nih.gov\/diseases\/FDS-orphan-drugs)\/7,000\" data-saferedirecturl=\"https:\/\/www.google.com\/url?q=https:\/\/www.rarediseases.info.nih.gov\/diseases\/FDS-orphan-drugs)\/7,000&amp;source=gmail&amp;ust=1617209033114000&amp;usg=AFQjCNGl8GC3JC7PBWSWbj-cHfQgWmhudQ\">https:\/\/www.rarediseases.info.nih.gov\/diseases\/FDS-orphan-drugs)\/7,000<\/a>\u00a0rare diseases for which the molecular basis is known (<a href=\"http:\/\/www.omim.org\/\" data-saferedirecturl=\"https:\/\/www.google.com\/url?q=http:\/\/www.OMIM.org&amp;source=gmail&amp;ust=1617209033114000&amp;usg=AFQjCNG6pGE6IFhDHqW6SGpJ5A14AfU7ZA\">www.OMIM.org<\/a>) =4.2%<\/p>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=&#8221;4.16&#8243; background_size=&#8221;initial&#8221; background_position=&#8221;top_left&#8221; background_repeat=&#8221;repeat&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;4_4&#8243; _builder_version=&#8221;4.16&#8243; custom_padding=&#8221;|||&#8221; global_colors_info=&#8221;{}&#8221; custom_padding__hover=&#8221;|||&#8221;][et_pb_text admin_label=&#8221;FDA&#8221; _builder_version=&#8221;4.16&#8243; text_font_size=&#8221;13px&#8221; background_size=&#8221;initial&#8221; background_position=&#8221;top_left&#8221; background_repeat=&#8221;repeat&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<p><span>**\u00a0<\/span><span>PRF would like to acknowledge the critical contributions of the scientists from Schering-Plough \/ Merck R&amp;D who supported<span class=\"m_-8175828865577728923apple-converted-space\">\u00a0<\/span>both the evaluation of lonafarnib in preclinical models of HGPS and the clinical studies in progeria patients. This<span class=\"m_-8175828865577728923apple-converted-space\">\u00a0<\/span>team, led by W. Robert Bishop, John Piwinski, Cecil Pickett, and Catherine Strader, supported pharmacokinetic \/ pharmacodynamic studies, optimized drug formulation and insured adequate drug supply throughout these studies. Members of this team included: Susan Arbuck,<span class=\"m_-8175828865577728923apple-converted-space\">\u00a0<\/span><\/span><span>Art Bertelsen, Alan Cooper, Emily Frank, David Harris, Georgianna Harris,<span class=\"m_-8175828865577728923apple-converted-space\">\u00a0<\/span>Paul Kirschmeier, Ming Liu, Jin-Keon Pai, Robert Patton, Paul Statkevich, Greg Szpunar, Bohdan Yaremko, Paul Zavodny, and Yali Zhu.<\/span><\/p>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>\u0645\u0648\u0696 \u062e\u0648\u0634\u062d\u0627\u0644\u0647 \u06cc\u0648 \u0686\u06d0 \u0627\u0639\u0644\u0627\u0646 \u0648\u06a9\u0693\u0648 \u0686\u06d0 \u0646\u0646 \u0648\u0631\u0681\u060c \u0645\u0648\u0696 \u062f PRF \u0645\u0627\u0645\u0648\u0631\u06cc\u062a \u06cc\u0648\u0647 \u0645\u0647\u0645\u0647 \u0628\u0631\u062e\u0647 \u062a\u0631\u0644\u0627\u0633\u0647 \u06a9\u0693\u0647: \u0644\u0648\u0646\u0627\u0641\u0631\u0646\u06cc\u0628\u060c \u062f \u067e\u0631\u0648\u062c\u06cc\u0631\u06cc\u0627 \u0644\u067e\u0627\u0631\u0647 \u0644\u0648\u0645\u0693\u06cc \u062f\u0631\u0645\u0644\u0646\u0647\u060c \u062f FDA \u062a\u0635\u0648\u06cc\u0628 \u062a\u0631\u0644\u0627\u0633\u0647 \u0634\u0648\u06cc. <\/p>","protected":false},"author":2,"featured_media":11491,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"on","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":"","_links_to":"","_links_to_target":""},"categories":[2,1],"tags":[],"class_list":["post-11488","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","category-uncategorized"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>The day has come: FDA approval for first-ever Progeria treatment! - The Progeria Research Foundation<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.progeriaresearch.org\/ps\/2020\/11\/20\/fda-approval\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"The day has come: FDA approval for first-ever Progeria treatment! - The Progeria Research Foundation\" \/>\n<meta property=\"og:description\" content=\"We\u2019re thrilled to announce that today, we achieved an important piece of PRF\u2019s mission: lonafarnib, the first-ever treatment for Progeria, has been granted FDA approval.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.progeriaresearch.org\/ps\/2020\/11\/20\/fda-approval\/\" \/>\n<meta property=\"og:site_name\" content=\"The Progeria Research Foundation\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/ProgeriaResearch\/\" \/>\n<meta property=\"article:published_time\" content=\"2020-11-20T23:02:39+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2022-11-14T22:17:52+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2020\/11\/posthpFDA-e1607461962809.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"200\" \/>\n\t<meta property=\"og:image:height\" content=\"199\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Karen Betournay\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@Progeria\" \/>\n<meta name=\"twitter:site\" content=\"@Progeria\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Karen Betournay\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.progeriaresearch.org\\\/id\\\/2020\\\/11\\\/20\\\/fda-approval\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.progeriaresearch.org\\\/id\\\/2020\\\/11\\\/20\\\/fda-approval\\\/\"},\"author\":{\"name\":\"Karen Betournay\",\"@id\":\"https:\\\/\\\/www.progeriaresearch.org\\\/ta\\\/#\\\/schema\\\/person\\\/2be6cec85c11aaef7a7602636c5b9946\"},\"headline\":\"The day has come: FDA approval for first-ever Progeria treatment!\",\"datePublished\":\"2020-11-20T23:02:39+00:00\",\"dateModified\":\"2022-11-14T22:17:52+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.progeriaresearch.org\\\/id\\\/2020\\\/11\\\/20\\\/fda-approval\\\/\"},\"wordCount\":593,\"publisher\":{\"@id\":\"https:\\\/\\\/www.progeriaresearch.org\\\/ta\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/www.progeriaresearch.org\\\/id\\\/2020\\\/11\\\/20\\\/fda-approval\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.progeriaresearch.org\\\/wp-content\\\/uploads\\\/2020\\\/11\\\/posthpFDA-e1607461962809.jpg\",\"articleSection\":[\"News\",\"Uncategorized\"],\"inLanguage\":\"ps\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.progeriaresearch.org\\\/id\\\/2020\\\/11\\\/20\\\/fda-approval\\\/\",\"url\":\"https:\\\/\\\/www.progeriaresearch.org\\\/id\\\/2020\\\/11\\\/20\\\/fda-approval\\\/\",\"name\":\"The day has come: FDA approval for first-ever Progeria treatment! - The Progeria Research Foundation\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.progeriaresearch.org\\\/ta\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.progeriaresearch.org\\\/id\\\/2020\\\/11\\\/20\\\/fda-approval\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.progeriaresearch.org\\\/id\\\/2020\\\/11\\\/20\\\/fda-approval\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.progeriaresearch.org\\\/wp-content\\\/uploads\\\/2020\\\/11\\\/posthpFDA-e1607461962809.jpg\",\"datePublished\":\"2020-11-20T23:02:39+00:00\",\"dateModified\":\"2022-11-14T22:17:52+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.progeriaresearch.org\\\/id\\\/2020\\\/11\\\/20\\\/fda-approval\\\/#breadcrumb\"},\"inLanguage\":\"ps\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.progeriaresearch.org\\\/id\\\/2020\\\/11\\\/20\\\/fda-approval\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"ps\",\"@id\":\"https:\\\/\\\/www.progeriaresearch.org\\\/id\\\/2020\\\/11\\\/20\\\/fda-approval\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.progeriaresearch.org\\\/wp-content\\\/uploads\\\/2020\\\/11\\\/posthpFDA-e1607461962809.jpg\",\"contentUrl\":\"https:\\\/\\\/www.progeriaresearch.org\\\/wp-content\\\/uploads\\\/2020\\\/11\\\/posthpFDA-e1607461962809.jpg\",\"width\":200,\"height\":199},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.progeriaresearch.org\\\/id\\\/2020\\\/11\\\/20\\\/fda-approval\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.progeriaresearch.org\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"The day has come: FDA approval for first-ever Progeria treatment!\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.progeriaresearch.org\\\/ta\\\/#website\",\"url\":\"https:\\\/\\\/www.progeriaresearch.org\\\/ta\\\/\",\"name\":\"The Progeria Research Foundation\",\"description\":\"For the Children \u2665 For the Cure\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.progeriaresearch.org\\\/ta\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.progeriaresearch.org\\\/ta\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"ps\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.progeriaresearch.org\\\/ta\\\/#organization\",\"name\":\"The Progeria Research Foundation\",\"url\":\"https:\\\/\\\/www.progeriaresearch.org\\\/ta\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"ps\",\"@id\":\"https:\\\/\\\/www.progeriaresearch.org\\\/ta\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.progeriaresearch.org\\\/wp-content\\\/uploads\\\/2019\\\/05\\\/PRF_Logo_2019_optimized.png\",\"contentUrl\":\"https:\\\/\\\/www.progeriaresearch.org\\\/wp-content\\\/uploads\\\/2019\\\/05\\\/PRF_Logo_2019_optimized.png\",\"width\":300,\"height\":86,\"caption\":\"The Progeria Research Foundation\"},\"image\":{\"@id\":\"https:\\\/\\\/www.progeriaresearch.org\\\/ta\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/ProgeriaResearch\\\/\",\"https:\\\/\\\/x.com\\\/Progeria\",\"https:\\\/\\\/www.instagram.com\\\/progeriaresearch\\\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.progeriaresearch.org\\\/ta\\\/#\\\/schema\\\/person\\\/2be6cec85c11aaef7a7602636c5b9946\",\"name\":\"Karen Betournay\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"ps\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/78c0520933a7d708c5e1a5788ec6799d5e2ad6a2a6d4ff2ca1e512861d12f533?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/78c0520933a7d708c5e1a5788ec6799d5e2ad6a2a6d4ff2ca1e512861d12f533?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/78c0520933a7d708c5e1a5788ec6799d5e2ad6a2a6d4ff2ca1e512861d12f533?s=96&d=mm&r=g\",\"caption\":\"Karen Betournay\"},\"url\":\"https:\\\/\\\/www.progeriaresearch.org\\\/ps\\\/author\\\/karenb\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"The day has come: FDA approval for first-ever Progeria treatment! - The Progeria Research Foundation","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.progeriaresearch.org\/ps\/2020\/11\/20\/fda-approval\/","og_locale":"en_US","og_type":"article","og_title":"The day has come: FDA approval for first-ever Progeria treatment! - The Progeria Research Foundation","og_description":"We\u2019re thrilled to announce that today, we achieved an important piece of PRF\u2019s mission: lonafarnib, the first-ever treatment for Progeria, has been granted FDA approval.","og_url":"https:\/\/www.progeriaresearch.org\/ps\/2020\/11\/20\/fda-approval\/","og_site_name":"The Progeria Research Foundation","article_publisher":"https:\/\/www.facebook.com\/ProgeriaResearch\/","article_published_time":"2020-11-20T23:02:39+00:00","article_modified_time":"2022-11-14T22:17:52+00:00","og_image":[{"width":200,"height":199,"url":"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2020\/11\/posthpFDA-e1607461962809.jpg","type":"image\/jpeg"}],"author":"Karen Betournay","twitter_card":"summary_large_image","twitter_creator":"@Progeria","twitter_site":"@Progeria","twitter_misc":{"Written by":"Karen Betournay","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.progeriaresearch.org\/id\/2020\/11\/20\/fda-approval\/#article","isPartOf":{"@id":"https:\/\/www.progeriaresearch.org\/id\/2020\/11\/20\/fda-approval\/"},"author":{"name":"Karen Betournay","@id":"https:\/\/www.progeriaresearch.org\/ta\/#\/schema\/person\/2be6cec85c11aaef7a7602636c5b9946"},"headline":"The day has come: FDA approval for first-ever Progeria treatment!","datePublished":"2020-11-20T23:02:39+00:00","dateModified":"2022-11-14T22:17:52+00:00","mainEntityOfPage":{"@id":"https:\/\/www.progeriaresearch.org\/id\/2020\/11\/20\/fda-approval\/"},"wordCount":593,"publisher":{"@id":"https:\/\/www.progeriaresearch.org\/ta\/#organization"},"image":{"@id":"https:\/\/www.progeriaresearch.org\/id\/2020\/11\/20\/fda-approval\/#primaryimage"},"thumbnailUrl":"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2020\/11\/posthpFDA-e1607461962809.jpg","articleSection":["News","Uncategorized"],"inLanguage":"ps"},{"@type":"WebPage","@id":"https:\/\/www.progeriaresearch.org\/id\/2020\/11\/20\/fda-approval\/","url":"https:\/\/www.progeriaresearch.org\/id\/2020\/11\/20\/fda-approval\/","name":"The day has come: FDA approval for first-ever Progeria treatment! - The Progeria Research Foundation","isPartOf":{"@id":"https:\/\/www.progeriaresearch.org\/ta\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.progeriaresearch.org\/id\/2020\/11\/20\/fda-approval\/#primaryimage"},"image":{"@id":"https:\/\/www.progeriaresearch.org\/id\/2020\/11\/20\/fda-approval\/#primaryimage"},"thumbnailUrl":"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2020\/11\/posthpFDA-e1607461962809.jpg","datePublished":"2020-11-20T23:02:39+00:00","dateModified":"2022-11-14T22:17:52+00:00","breadcrumb":{"@id":"https:\/\/www.progeriaresearch.org\/id\/2020\/11\/20\/fda-approval\/#breadcrumb"},"inLanguage":"ps","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.progeriaresearch.org\/id\/2020\/11\/20\/fda-approval\/"]}]},{"@type":"ImageObject","inLanguage":"ps","@id":"https:\/\/www.progeriaresearch.org\/id\/2020\/11\/20\/fda-approval\/#primaryimage","url":"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2020\/11\/posthpFDA-e1607461962809.jpg","contentUrl":"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2020\/11\/posthpFDA-e1607461962809.jpg","width":200,"height":199},{"@type":"BreadcrumbList","@id":"https:\/\/www.progeriaresearch.org\/id\/2020\/11\/20\/fda-approval\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.progeriaresearch.org\/"},{"@type":"ListItem","position":2,"name":"The day has come: FDA approval for first-ever Progeria treatment!"}]},{"@type":"WebSite","@id":"https:\/\/www.progeriaresearch.org\/ta\/#website","url":"https:\/\/www.progeriaresearch.org\/ta\/","name":"\u062f \u067e\u0631\u0648\u062c\u06cc\u0631\u06cc\u0627 \u0685\u06cc\u0693\u0646\u06cc\u0632 \u0628\u0646\u0633\u067c","description":"\u062f \u0645\u0627\u0634\u0648\u0645\u0627\u0646\u0648 \u0644\u067e\u0627\u0631\u0647 \u2665 \u062f \u062f\u0631\u0645\u0644\u0646\u06d0 \u0644\u067e\u0627\u0631\u0647","publisher":{"@id":"https:\/\/www.progeriaresearch.org\/ta\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.progeriaresearch.org\/ta\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"ps"},{"@type":"Organization","@id":"https:\/\/www.progeriaresearch.org\/ta\/#organization","name":"\u062f \u067e\u0631\u0648\u062c\u06cc\u0631\u06cc\u0627 \u0685\u06cc\u0693\u0646\u06cc\u0632 \u0628\u0646\u0633\u067c","url":"https:\/\/www.progeriaresearch.org\/ta\/","logo":{"@type":"ImageObject","inLanguage":"ps","@id":"https:\/\/www.progeriaresearch.org\/ta\/#\/schema\/logo\/image\/","url":"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2019\/05\/PRF_Logo_2019_optimized.png","contentUrl":"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2019\/05\/PRF_Logo_2019_optimized.png","width":300,"height":86,"caption":"The Progeria Research Foundation"},"image":{"@id":"https:\/\/www.progeriaresearch.org\/ta\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/ProgeriaResearch\/","https:\/\/x.com\/Progeria","https:\/\/www.instagram.com\/progeriaresearch\/"]},{"@type":"Person","@id":"https:\/\/www.progeriaresearch.org\/ta\/#\/schema\/person\/2be6cec85c11aaef7a7602636c5b9946","name":"\u06a9\u0627\u0631\u0646 \u0628\u06cc\u067c\u0648\u0631\u0646\u064a","image":{"@type":"ImageObject","inLanguage":"ps","@id":"https:\/\/secure.gravatar.com\/avatar\/78c0520933a7d708c5e1a5788ec6799d5e2ad6a2a6d4ff2ca1e512861d12f533?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/78c0520933a7d708c5e1a5788ec6799d5e2ad6a2a6d4ff2ca1e512861d12f533?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/78c0520933a7d708c5e1a5788ec6799d5e2ad6a2a6d4ff2ca1e512861d12f533?s=96&d=mm&r=g","caption":"Karen Betournay"},"url":"https:\/\/www.progeriaresearch.org\/ps\/author\/karenb\/"}]}},"_links":{"self":[{"href":"https:\/\/www.progeriaresearch.org\/ps\/wp-json\/wp\/v2\/posts\/11488","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.progeriaresearch.org\/ps\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.progeriaresearch.org\/ps\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.progeriaresearch.org\/ps\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.progeriaresearch.org\/ps\/wp-json\/wp\/v2\/comments?post=11488"}],"version-history":[{"count":0,"href":"https:\/\/www.progeriaresearch.org\/ps\/wp-json\/wp\/v2\/posts\/11488\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.progeriaresearch.org\/ps\/wp-json\/wp\/v2\/media\/11491"}],"wp:attachment":[{"href":"https:\/\/www.progeriaresearch.org\/ps\/wp-json\/wp\/v2\/media?parent=11488"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.progeriaresearch.org\/ps\/wp-json\/wp\/v2\/categories?post=11488"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.progeriaresearch.org\/ps\/wp-json\/wp\/v2\/tags?post=11488"}],"curies":[{"name":"\u0689\u0628\u0644\u06cc\u0648 \u067e\u064a","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}